| 33 0.64 (1.98%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 43.06 | 1-year : | 50.3 |
| Resists | First : | 36.87 | Second : | 43.06 |
| Pivot price | 31.58 |
|||
| Supports | First : | 31.45 |
Second : | 28.11 |
| MAs | MA(5) : | 32.45 |
MA(20) : | 31.96  |
| MA(100) : | 35.2 |
MA(250) : | 22.58 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 44.7 |
D(3) : | 44.6 |
| RSI | RSI(14): 53.2 |
|||
| 52-week | High : | 79.01 | Low : | 0.93 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DRUG ] has closed below upper band by 17.3%. Bollinger Bands are 54.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 34.91 - 35.05 | 35.05 - 35.2 |
| Low: | 31.79 - 31.92 | 31.92 - 32.08 |
| Close: | 32.74 - 32.96 | 32.96 - 33.22 |
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Tue, 13 May 2025
TD Cowen Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation - Nasdaq
Tue, 13 May 2025
TD Cowen Initiates Coverage on Bright Minds Biosciences (DRUG) w - GuruFocus
Tue, 13 May 2025
Bright Minds stock rating initiated with Buy at TD Cowen By Investing.com - Investing.com Nigeria
Tue, 13 May 2025
Bright Minds Biosciences Says BMB-101 Eliminated Drop Attacks in Mouse Model of Epilepsy - marketscreener.com
Tue, 13 May 2025
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 - Stock Titan
Tue, 13 May 2025
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 22.5 (%) |
| Held by Institutions | 79.2 (%) |
| Shares Short | 87 (K) |
| Shares Short P.Month | 100 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -5 % |
| Return on Equity (ttm) | -3.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -235.72 |
| PEG Ratio | 0 |
| Price to Book value | 3.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -92.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|